Mainz Biomed N.V. (MYNZ), a leader in molecular genetics diagnostics, announced on Monday that it has reestablished compliance with Nasdaq's ongoing listing standards. On January 23, 2025, Nasdaq officially confirmed that the company satisfied the minimum stockholders' equity requirement as per Nasdaq Listing Rule 5550(b)(1).
Previously, Mainz Biomed had already met the minimum bid price requirement according to Rule 5550(a)(2). As a result, the company is now in full compliance with all Nasdaq listing regulations and will remain listed on the Nasdaq Capital Market.
Mainz Biomed is dedicated to the early detection of cancer, with its flagship product, ColoAlert, offering a non-invasive test for colorectal cancer. The company is also making strides in developing other diagnostic solutions, such as PancAlert, focused on the early detection of pancreatic cancer.
At present, MYNZ shares are trading at $4.53, reflecting an increase of 0.89%.
